32. Prioritize the pediatric TB diagnostic space to ensure there are improved tools for pediatric TB infection and disease detection to reach and maintain targets.
33. Develop quality-assured, affordable, less invasive alternative specimen processing methods or products (not based only on sputum) that can be used for the pediatric population, such as urine, stool or saliva.
34. Ensure diagnostic studies include children and alternative (non-sputum-based) sample types.
35. Expedite development of point-of-care biomarker-based tests for infants and children.
36. Consider moving from separate instrument, consumable, and service procurement towards more consolidated, all-inclusive pricing models, for both laboratory-based and point-of-care technologies.
37. Provide service level agreements that clearly spell out key performance indicators for all technology types and their offered service plans, plus a mitigation plan when the threshold is exceeded.
66. Prioritize regulatory approvals where required for introduction of Truenat TB tests in additional high TB burden countries.
67. Share a plan for service and other forms of technical support in international settings with international partners for comment and transparent review/ implementation.
68. Proactively define standardized Key Performance Indicators for system and test performance.
69. Prioritize the regulatory processes of HIV assays for infant diagnosis and viral load.
70. Offer access pricing and prospective reductions based on global volume thresholds; publish the volumes procured quarterly.
71. Prioritise the development of resistance markers for TB as well as multiple sample types and to work on a TB +COVID test.